Skip to content
sellWeak cluster of 310b5-1 plan

Klinger Shannon Thyme sold $24k of MRNA

Chief Legal Officer at Moderna, Inc.. 529 shares at an average of $44.68, traded Dec 9, 2024, filed Dec 10, 2024.

Warning score
0
Value
$24k
529 shares
Holdings after
20,446
-3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001127602-24-028963, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 6, 2024MOption exercise
Common Stock10b5-1
+1,138--20,975Dec 10, 2024
Dec 9, 2024SOpen-market sale
Common Stock10b5-1
-529$44.68$24k20,446Dec 10, 2024
Dec 6, 2024MOption exercise
Restricted Stock Unitsderivative10b5-1
-1,138$0.00$02,278Dec 10, 2024

Related signals

Other insiders at Moderna, Inc. and this insider’s other filings.

ScoreSideCompanyInsiderValueSharesFiled
50ModeratebuyMRNA
Moderna, Inc.
Bancel Stephane
Chief Executive Officer
$5.0M160,314
0Weaksell 310b5-1MRNA
Moderna, Inc.
Hoge Stephen
President
$14k314
0Weaksell 310b5-1MRNA
Moderna, Inc.
Klinger Shannon Thyme
Chief Legal Officer
$4,849112
0Weaksell 310b5-1MRNA
Moderna, Inc.
Hoge Stephen
President
$12k291
2Weaksell 310b5-1MRNA
Moderna, Inc.
Klinger Shannon Thyme
Chief Legal Officer
$61k1,418
14Weaksell 310b5-1MRNA
Moderna, Inc.
Mock James M
Chief Financial Officer
$61k1,420
0Weaksell10b5-1MRNA
Moderna, Inc.
Hoge Stephen
President
$13k277

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Klinger Shannon Thyme sold $24k of MRNA | InsiderTell